Christopher Semder, MD
Interventional Cardiology · Louisville, KYNPI 1487858965
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 74.9% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $16,442 and has fallen 96.3% since, to $611 in 2025.
Across 285 payments — averaging $174.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$37K
- Abbott$7K
- Medtronic$2K
- Philips North America LLC$1K
- Terumo Medical Corporation$844
- Edwards Lifesciences$536
- plus $1K from 21 others
Across 44 payments — averaging $1213.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$28K
- Boston Scientific$25K
What the payments were for
- Consulting fees$3,6007%
- Speaking & faculty fees$22,75046%
- Travel & lodging$12,52425%
- Food & beverage$10,84322%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 93 | $37,281 |
| Abbott | 93 | $7,118 |
| Medtronic(2 entities) | 11 | $1,564 |
| Philips North America LLC | 2 | $1,036 |
| Terumo Medical Corporation | 15 | $844 |
| Edwards Lifesciences | 5 | $536 |
| EKOS Corporation | 5 | $285 |
| Pfizer | 11 | $187 |
| Biotronik Inc. | 1 | $94 |
| Johnson & Johnson | 7 | $93 |
| Inari Medical, Inc. | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 6 | $84 |
| Abiomed | 3 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Novartis | 4 | $59 |
| AstraZeneca | 4 | $56 |
| Novo Nordisk | 3 | $44 |
| Amgen | 3 | $42 |
| Boehringer Ingelheim | 2 | $40 |
| Cardiva Medical, Inc. | 1 | $25 |
| Surmodics, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Atricure, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EKOSONIC$21,619
- AngioJet Ultra 5000A$7,936
- AMPLATZER AMULET$1,527
- Mitra Clip system$1,095
- Azurion 7 B20$1,036
- CoreValve Evolut$1,022
- GENERAL VASCULAR INTERVENTION$602
- SAPIEN 3 Ultra RESILIA$466
- AMPLATZER$409
- MitraClip$360
- Simulus$146
- MetaCross$144
- WATCHMAN Access System$143
- Optitorque$114
- METACROSS OTW$107
How this compares
$49,743 in reported general payments places this provider in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 239 | $278,918 |
| XareltoRivaroxaban | 52 | $66,087 |
| EntrestoSacubitril/Valsartan | 50 | $56,944 |
| Repatha SureclickEvolocumab | 61 | $39,997 |
| JardianceEmpagliflozin | 23 | $22,369 |
| BrilintaTicagrelor | 24 | $15,179 |
| Praluent PenAlirocumab | 22 | $10,757 |
| Ranolazine ErRanolazine | 17 | $3,983 |
| Metoprolol Succinate | 243 | $3,743 |
| ClopidogrelClopidogrel Bisulfate | 291 | $2,956 |
| Ezetimibe | 73 | $2,749 |
| Midodrine Hcl | 12 | $2,062 |
| Atorvastatin Calcium | 304 | $2,023 |
| Carvedilol | 251 | $1,667 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $1,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $187 | $278,918239 claims |
| Johnson & JohnsonXarelto | $93 | $66,08752 claims |
| NovartisEntresto | $59 | $56,94450 claims |
| Boehringer IngelheimJardiance | $40 | $22,36923 claims |
| AstraZenecaBrilinta | $56 | $15,17924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Louisville
- Daniel StewartLouisville$290K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ravi SharmaLouisville$86K
- Sadip PantLouisville$43K
- Michael FlahertyLouisville$42K
- Prafull RahejaLouisville$27K
- Faraaz RahmanLouisville$22K
- Hussayn AlrayesLouisville$21K
- Ivan PenaLouisville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.